Inhaled beta2-agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Inhaled beta2-agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists. / Jeppesen, Jan S.; Jessen, Søren; Thomassen, Martin; Backer, Vibeke; Bangsbo, Jens; Hostrup, Morten.
I: Scandinavian Journal of Medicine and Science in Sports, Bind 34, Nr. 1, e14500, 2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Inhaled beta2-agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists
AU - Jeppesen, Jan S.
AU - Jessen, Søren
AU - Thomassen, Martin
AU - Backer, Vibeke
AU - Bangsbo, Jens
AU - Hostrup, Morten
N1 - Publisher Copyright: © 2023 The Authors. Scandinavian Journal of Medicine & Science In Sports published by John Wiley & Sons Ltd.
PY - 2024
Y1 - 2024
N2 - Purpose: Many athletes use long-acting beta2-agonist formoterol in treatment of asthma. However, studies in non-athlete cohorts demonstrate that inhaled formoterol can enhance sprint performance calling into question whether its use in competitive sports should be restricted. We investigated whether formoterol at upper recommended inhaled doses (54 μg) would enhance sprint ability and intense exercise performance in elite cyclists. Methods: Twenty-one male cyclists (V̇O2max: 70.4 ± 4.3 mL × min−1 × kg−1, mean ± SD) completed two 6-s all-out sprints followed by 4-min all-out cycling after inhaling either 54 μg formoterol or placebo. We also assessed cyclists' leg muscle mass by dual-energy X-ray absorptiometry and muscle fiber type distribution of vastus lateralis biopsies. Results: Peak and mean power output during the 6-s sprint was 32 W (95% CI, 19–44 W, p < 0.001) and 36 W (95% CI, 24–48 W, p < 0.001) higher with formoterol than placebo, corresponding to an enhancing effect of around 3%. Power output during 4-min all-out cycling was 9 W (95% CI, 2–16 W, p = 0.01) greater with formoterol than placebo, corresponding to an enhancing effect of 2.3%. Performance changes in response to formoterol were unrelated to cyclists' VO2max and leg lean mass, whereas muscle fiber Type I distribution correlated with change in sprinting peak power in response to formoterol (r2 = 0.314, p = 0.012). Conclusion: Our findings demonstrate that an inhaled one-off dose of 54 μg formoterol has a performance-enhancing potential on sprint ability and short intense performance in elite male cyclists, which is irrespective of training status but partly related to muscle fiber type distribution for sprint ability.
AB - Purpose: Many athletes use long-acting beta2-agonist formoterol in treatment of asthma. However, studies in non-athlete cohorts demonstrate that inhaled formoterol can enhance sprint performance calling into question whether its use in competitive sports should be restricted. We investigated whether formoterol at upper recommended inhaled doses (54 μg) would enhance sprint ability and intense exercise performance in elite cyclists. Methods: Twenty-one male cyclists (V̇O2max: 70.4 ± 4.3 mL × min−1 × kg−1, mean ± SD) completed two 6-s all-out sprints followed by 4-min all-out cycling after inhaling either 54 μg formoterol or placebo. We also assessed cyclists' leg muscle mass by dual-energy X-ray absorptiometry and muscle fiber type distribution of vastus lateralis biopsies. Results: Peak and mean power output during the 6-s sprint was 32 W (95% CI, 19–44 W, p < 0.001) and 36 W (95% CI, 24–48 W, p < 0.001) higher with formoterol than placebo, corresponding to an enhancing effect of around 3%. Power output during 4-min all-out cycling was 9 W (95% CI, 2–16 W, p = 0.01) greater with formoterol than placebo, corresponding to an enhancing effect of 2.3%. Performance changes in response to formoterol were unrelated to cyclists' VO2max and leg lean mass, whereas muscle fiber Type I distribution correlated with change in sprinting peak power in response to formoterol (r2 = 0.314, p = 0.012). Conclusion: Our findings demonstrate that an inhaled one-off dose of 54 μg formoterol has a performance-enhancing potential on sprint ability and short intense performance in elite male cyclists, which is irrespective of training status but partly related to muscle fiber type distribution for sprint ability.
KW - anti-doping
KW - beta-agonists
KW - ergogenic
KW - intense exercise capacity
KW - LABA
KW - performance
KW - SABA
KW - sprinting ability
U2 - 10.1111/sms.14500
DO - 10.1111/sms.14500
M3 - Journal article
C2 - 37880916
AN - SCOPUS:85174820859
VL - 34
JO - Scandinavian Journal of Medicine & Science in Sports
JF - Scandinavian Journal of Medicine & Science in Sports
SN - 0905-7188
IS - 1
M1 - e14500
ER -
ID: 375720724